Loading...
DR Reddy S Laboratories Limited — Fulvestrant Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #6 for Fulvestrant · $450.0K export value · DGFT Verified
DR Reddy S Laboratories Limited is the #6 Indian exporter of Fulvestrant with $450.0K in export value and 9 verified shipments. DR Reddy S Laboratories Limited holds a 3.1% market share in Fulvestrant exports across 6 countries. The company exports 50 pharmaceutical products worth $310.6M across 19 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $1.9M | 37 | 20.7% |
| ITALY | $1.0M | 20 | 11.2% |
| NETHERLANDS | $989.4K | 25 | 11.1% |
| BELGIUM | $950.0K | 19 | 10.6% |
| BRAZIL | $850.0K | 17 | 9.5% |
| SPAIN | $829.9K | 20 | 9.3% |
| POLAND | $564.2K | 13 | 6.3% |
| MALTA | $496.3K | 74 | 5.6% |
| SRI LANKA | $350.0K | 7 | 3.9% |
| VENEZUELA | $252.5K | 6 | 2.8% |
India exports Fulvestrant to 66 countries. The top destination is UNITED STATES (20.7%), followed by ITALY and NETHERLANDS.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| YUSEN LOGISTICS BENELUX BELGIUM | BELGIUM | $950.0K | 19 |
| FARMAVENIX | SPAIN | $744.9K | 17 |
| ACCORD HEALTHCARE ITALIA SRL | ITALY | $400.0K | 8 |
| BROCACEF NL : HUB | NETHERLANDS | $399.3K | 14 |
| EUGIA PHARMA (MALTA) LTD, | MALTA | $350.0K | 7 |
India exported $8.6M worth of Fulvestrant through 487 shipments from 84 suppliers to 66 countries, serving 148 buyers globally. DR Reddy S Laboratories Limited contributes $450.0K to this total, accounting for 3.1% of India's Fulvestrant exports.
DR Reddy S Laboratories Limited's average Fulvestrant shipment value is $50.0K per consignment, based on 9 shipments totaling $450.0K.
DR Reddy S Laboratories Limited ranks #6 among 84 Indian Fulvestrant exporters with a 3.1% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($4.4M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($1.1M), DR REDDYS LABORATORIES LIMITED ($650.0K). DR Reddy S Laboratories Limited processed 9 shipments to 6 destination countries.
What DR Reddy S Laboratories Limited must comply with to export Fulvestrant to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #6 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | DR REDDYS LABORATORIES LIMITED | $650.0K | 13 | 6 | $50.0K |
| 2 | JODAS EXPOIM PRIVATE LIMITED | $550.0K | 11 | 3 | $50.0K |
| 6 | DR REDDY S LABORATORIES LIMITED ★ | $450.0K | 9 | 6 | $50.0K |
| 7 | EUGIA PHARMA SPECIALITIES LIMITED | $400.0K | 8 |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 98 | 20.1% |
| AHEMDABAD AIR ACC (INAMD4) | 71 | 14.6% |
| SAHAR AIR CARGO ACC (INBOM4) | 56 | 11.5% |
| Bombay Air | 33 | 6.8% |
| MUNDRA SEA (INMUN1) | 24 | 4.9% |
| AHEMDABAD AIR | 24 | 4.9% |
| DELHI AIR | 21 | 4.3% |
| DELHI AIR CARGO ACC (INDEL4) | 17 | 3.5% |
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Dr. Reddy's. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times. This situation necessitates strategic logistics planning to mitigate potential delays and cost escalations.
Conversely, the ongoing US-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, creating opportunities for Indian exporters. Dr. Reddy's, with its established presence and compliance with stringent regulatory standards, is well-positioned to capitalize on this shift.
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement. Dr. Reddy's commitment to quality and regulatory adherence ensures its continued access to the EU market, despite the evolving regulatory landscape.
Maintaining compliance with international regulatory standards is paramount for Dr. Reddy's. The company has consistently adhered to FDA, WHO, and EU Good Manufacturing Practices (GMP), ensuring the quality and safety of its products. This commitment is crucial in sustaining trust and credibility in global markets.
However, regulatory challenges persist. In April 2025, Dr. Reddy's received a show cause notice from the Indian Income Tax Department concerning a proposed demand of over ₹2,395 crore related to the merger of Dr. Reddy's Holding Ltd with itself. The company has stated its belief that there is no tax liability arising from the merger and is addressing the matter through appropriate channels. (business-standard.com)
DR Reddy S Laboratories Limited exports 50 products worth $310.6M. Beyond Fulvestrant, top products include Metoprolol, Omeprazole, Fexofenadine, Clopidogrel, Esomeprazole. View the complete DR Reddy S Laboratories Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Fulvestrant — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for DR Reddy S Laboratories Limited's Fulvestrant exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
DR Reddy S Laboratories Limited
Full Company Profile →
50 products · $310.6M total trade · 19 categories
| UNITED STATES |
| $250.0K |
| 5 |
| SOFTCARE INTERNATIONAL(PVT)LTD | SRI LANKA | $250.0K | 5 |
| XXNEAXXEU XXMITXX | UNITED STATES | $200.0K | 4 |
| DR REDDYS LABORATORIES INC | UNITED STATES | $150.0K | 3 |
| OOOJODAS EXPOIM | RUSSIA | $100.0K | 2 |
India's Fulvestrant is purchased by 148 buyers worldwide. The top buyer is YUSEN LOGISTICS BENELUX BELGIUM (BELGIUM), followed by FARMAVENIX and ACCORD HEALTHCARE ITALIA SRL.
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 2 |
| $50.0K |
| 5 | ALEMBIC PHARMACEUTICALS LIMITED | $350.0K | 7 | 1 | $50.0K |
DR Reddy S Laboratories Limited ranks #6 among 84 Indian Fulvestrant exporters. Average shipment value of $50.0K compared to the market average of $102.9K. The closest competitors by value are DR REDDYS LABORATORIES LIMITED and JODAS EXPOIM PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 66+ countries, 148+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for DR Reddy S Laboratories Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Fulvestrant. For current shipment-level data, contact TransData Nexus.